Wei Xia

机构：Second Military Medical University, Shanghai University of Traditional Chinese Medicine, Shanghai Traditional Chinese Medicine Hospital, Shanghai Pudong New Area Gongli Hospital, Jiangsu Province Hospital, Pudong New Area People's Hospital, Nanjing Medical University · ORCID：0000-0002-4171-5008

发表论文 55 篇 · 总被引 1077 次 · h-index 20

代表论文

• PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer (2019 · Journal of Translational Medicine · 被引 63)
• lncRNA miR4458HG modulates hepatocellular carcinoma progression by activating m6A-dependent glycolysis and promoting the polarization of tumor-associated macrophages (2023 · Cellular and Molecular Life Sciences · 被引 46)
• RBMX contributes to hepatocellular carcinoma progression and sorafenib resistance by specifically binding and stabilizing BLACAT1. (2020 · PubMed · 被引 46)
• P4HB modulates epithelial‑mesenchymal transition and the β‑catenin/Snail pathway influencing chemoresistance in liver cancer cells (2020 · Oncology Letters · 被引 43)
• Physical exercise reverses immuno-cold tumor microenvironment via inhibiting SQLE in non-small cell lung cancer (2023 · Military Medical Research · 被引 40)
• GINS2 affects cell viability, cell apoptosis, and cell cycle progression of pancreatic cancer cells via MAPK/ERK pathway (2020 · Journal of Cancer · 被引 23)